Skip to main content

Table 5 Lipid parametersa in the all-exposed population (n = 4,009)

From: Integrated safety in tocilizumab clinical trials

Parameter (mg/dl) Baseline Week 6 Week 52b Week 104
Mean total cholesterol 196.2
(n = 3,714)
227.6
(n = 3,279)
222.9
(n = 1,312)
224.1
(n = 828)
Mean LDL cholesterol 114.2
(n = 3,633)
135.5
(n = 3,149)
133.5
(n = 1,274)
134.3
(n = 805)
Mean HDL cholesterol 56.9
(n = 3,656)
60.8
(n = 3,249)
60.0
(n = 1,301)
60.0
(n = 826)
Mean triglycerides 127.6
(n = 3,715)
160.4
(n = 3,280)
148.8
(n = 1,312)
148.8
(n = 828)
Patients starting lipid-lowering medication
at any time up to week 104 during the trial (n = 456)
Mean total cholesterol 223.3
(n = 415)
267.4
(n = 375)
247.7
(n = 154)
236.1
(n = 109)
Mean LDL cholesterol 135.1
(n = 402)
167.6
(n = 338)
152.9
(n = 142)
138.9
(n = 97)
  1. HDL, high-density lipoprotein; LDL, low-density lipoprotein. aFasted samples only. bPatient numbers declined after week 6 because patients' 12-week fasted lipid-analysis schedules might not have coincided with week 52, depending on when they started tocilizumab treatment (that is, some patients had their fasted lipid analysis at week 48 or week 56).